US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

Ophthalmology: market research reports

A portion of ophthalmology that resists change unlike some other specialties is the consumer reluctance to undertake a procedure that may have side effects associated with vision like refractive laser correction. Any side effects concerning eyes/vision is typically avoided as much as possible especially if there are other options.
Typically if the out-of pocket price for a life-enhancing procedure is within the budget of a consumer, the patient has a strong desire to get the procedure, and other factors are present that allow for it, the procedure is undertaken. In laser correction there has been skepticism which has diminished as more patients undertake the procedure with good results. While new ideas, breakthrough technologies, cost efficiencies, increased productivity,and new markets are the keys to growth and competitiveness, most people [work force; consumers; academics; politicians] are more confident in familiar environments. They will resist change unless their job, livelihood, or lifestyles are threatened.

This phenomenon is partly responsible for the trend toward closing solo and small group practices to join vision care networks. Though this experience exists more in general medical practices and some pecialties, ophthalmologists also face the threat of practitioners [osteopathic physicians, doctors of optometry] replacing eye MDs—an intrusion on their medical training, skills, and specialty. However increasing healthcare costs, and economic changes sometimes force shifts in the typical work pattern of healthcare providers. One example is a change that has happened in states across the U.S. allowing optometrists to diagnose and treat glaucoma.

RSS Feeds

Ophthalmology market research reports and industry analysis

< prev 1    3  4  5  6  7  8  9  10  
Sustained Release Ocular Drug Delivery Systems Market, 2014-2024
4/8/2014 | published by: Roots Analysis
... Several barriers have to be overcome for successful ocular drug delivery. For example, dilution of a drug by tears, clearance of a drug by the lymphatic system of conjunctiva, drug permeation issues with respect to ...  |  read more...
$1,899.00
Ophthalmic Drugs; Data, Analysis and Forecasts to 2024
3/4/2014 | published by: GMR Data Ltd.
... years? Which trial drugs are likely to make an impact? Only one report will tell you the answers. Simply by ordering and reading GMR Data’s new ‘Ophthalmic Drugs; Data, Analysis and Forecasts to 2024’ report, ...  |  read more...
$2,450.00
Age Related Macular Degeneration Global Clinical Trials Review, H1, 2014
2/28/2014 | published by: GlobalData
... trial scenario. This report provides elemental information and data relating to the clinical trials on Age Related Macular Degeneration. It includes an overview of the trial numbers and their recruitment status as per the site ...  |  read more...
$2,500.00
Open-Angle Glaucoma - Pipeline Review, H1 2014
2/28/2014 | published by: Global Markets Direct
... therapeutic development for Open-Angle Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news ...  |  read more...
$2,000.00
Glaucoma - Pipeline Review, H1 2014
2/28/2014 | published by: Global Markets Direct
... Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It ...  |  read more...
$2,000.00
Age Related Macular Degeneration - Pipeline Review, H1 2014
2/28/2014 | published by: Global Markets Direct
... report provides comprehensive information on the therapeutic development for Age Related Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule ...  |  read more...
$2,000.00
Ophthalmics Partnering Terms and Agreements
2/1/2014 | published by: Current Partnering
... or development stage whereby the licensee obtains a right or an option right to license the licensors ophthalmics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This report ...  |  read more...
$2,995.00
Dry Eye Partnering 2009-2014
2/1/2014 | published by: Current Partnering
... deals Top dry eye deals by value Deals listed by company A-Z, industry sector, stage of development, technology type Dry Eye Partnering 2009-2014 provides understanding and access to the dry eye partnering deals and agreements ...  |  read more...
$995.00
Age-related Macular Degeneration Partnering 2009-2014
2/1/2014 | published by: Current Partnering
... age-related macular degeneration partnering deals Top age-related macular degeneration deals by value Deals listed by company A-Z, industry sector, stage of development, technology type Age-related Macular Degeneration Partnering 2009-2014 provides understanding and access to the ...  |  read more...
$995.00
Glaucoma Partnering 2009-2014
2/1/2014 | published by: Current Partnering
... by value Deals listed by company A-Z, industry sector, stage of development, technology type Glaucoma Partnering 2009-2014 provides understanding and access to the glaucoma partnering deals and agreements entered into by the worlds leading healthcare ...  |  read more...
$995.00
Ophthalmics Deals and Alliances of 2013
2/1/2014 | published by: Current Partnering
... during 2013. Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report series allows you to view all the partnering and alliances deals announced worldwide. ...  |  read more...
$1,495.00
Conjunctivitis Partnering 2009-2014
2/1/2014 | published by: Current Partnering
... by value Deals listed by company A-Z, industry sector, stage of development, technology type Conjunctivitis Partnering 2009-2014 provides understanding and access to the conjunctivitis partnering deals and agreements entered into by the worlds leading healthcare ...  |  read more...
$995.00
Optometrists in the US - Industry Market Research Report
1/31/2014 | published by: IBISWorld
... delayed eye examinations begin to make appointments again. Aging baby boomers and a rise in the number of insured individuals will likely aid business significantly for industry operators, but competition from eye glasses and contact ...  |  read more...
$1,020.00
Optometrists in the US - Industry Risk Rating Report
1/27/2014 | published by: IBISWorld
... Risk is assumed to be 'the difficulty, or otherwise, of the business operating environment'. The report looks at the operational risk associated with this industry. Three types of risk are recognized in our analysis. These ...  |  read more...
$1,020.00
Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2014-2024
1/22/2014 | published by: Visiongain
... brand new report shows you potential revenues to 2024, assessing data, trends, opportunities and prospects there. Our 235 page report provides 152 tables, charts, and graphs. Discover the most lucrative areas in the industry and ...  |  read more...
$2,788.00
Manufacturing Opticians (UK) - Industry Report
1/8/2014 | published by: Plimsoll Publishing Ltd.
... and ELLIVRON INVESTMENTS LTD. This report covers activities such as lenses, glasses, contact lenses, spectacles, optician and includes a wealth of information on the financial trends over the past four years. Plimsoll Publishing’s latest Manufacturing ...  |  read more...
$525.00
Retinal Degeneration - Pipeline Review, H2 2013
12/31/2013 | published by: Global Markets Direct
... for Retinal Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Retinal Degeneration. Retinal Degeneration - Pipeline Review, Half Year ...  |  read more...
$2,000.00
OpportunityAnalyzer: Uveitis - Opportunity Analysis and Forecasts to 2017
12/30/2013 | published by: GlobalData
... is only effective in 50-60% of patients a significant number of patients can be targeted with the new treatment options. While anterior uveitis patients represent the majority of patients, all but one of the new ...  |  read more...
$5,995.00
Uveitis Global Clinical Trials Review, H2, 2013
12/30/2013 | published by: GlobalData
... relating to the clinical trials on Uveitis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage ...  |  read more...
$2,500.00
Analysis of the US Retinal Therapeutics Market
12/11/2013 | published by: Frost & Sullivan
... edema, and retinal vein occlusion due to their high efficacy and safety. This research service evaluates the US market for the pharmaceutical management of AMD, DME, and RVO from 2009 to 2017, with 2012 as ...  |  read more...
$6,000.00
Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Market 2014-2024
12/2/2013 | published by: Visiongain
... Visiongain's updated report forecasts those pharma revenues. There you find outlooks for sales growth in that industry. You also explore trends, technologies, therapies, and opportunities. That analysis gives you predictions of revenues to 2024 at ...  |  read more...
$2,788.00
Ophthalmics Partnering Terms & Agreements
12/1/2013 | published by: Current Partnering
... licensee obtains a right or an option right to license the licensors opthalmics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This report provides details of the latest ...  |  read more...
$2,995.00
U.S. Market and Survey for Retinopathy Screening Devices
12/1/2013 | published by: iData Research, Inc.
... determined by pricing and reimbursement. Several different strategies to promote widespread screening for diabetic retinopathy are being implemented across the United States and around the world. In the U.S., the success of these strategies will ...  |  read more...
$6,995.00
Ocular Disorders: Rising Therapeutics, Technologies, and Devices
12/1/2013 | published by: CHI Insight Pharma Reports
... including wet and dry age-related macular degeneration (AMD) while alsoproviding alternative therapeutic options for various ocular complications. In an interview with several companies including Oraya Therapeutics, VisionCare Ophthalmic Technologies, Omeros, and Kala Pharmaceuticals, representatives mentioned ...  |  read more...
$1,995.00
Ophthalmology Therapeutics in Major Developed Markets to 2019 - New Drug Approvals and Promising Pipeline to Trigger Shift in Treatment Paradigm to Combination Therapies
11/30/2013 | published by: GBI Research
... in Major Developed Markets to 2019 - New Drug Approvals and Promising Pipeline to Trigger Shift in Treatment Paradigm to Combination Therapies, which provides insights into two therapeutic indications in ophthalmology in Top Eight Markets ...  |  read more...
$3,500.00
< prev 1    3  4  5  6  7  8  9  10  
 
Our Clients